150 related articles for article (PubMed ID: 20085590)
1. Bmi-1 gene is upregulated in early-stage hepatocellular carcinoma and correlates with ATP-binding cassette transporter B1 expression.
Effendi K; Mori T; Komuta M; Masugi Y; Du W; Sakamoto M
Cancer Sci; 2010 Mar; 101(3):666-72. PubMed ID: 20085590
[TBL] [Abstract][Full Text] [Related]
2. Molecular pathology in early hepatocarcinogenesis.
Effendi K; Sakamoto M
Oncology; 2010; 78(2):157-60. PubMed ID: 20389138
[TBL] [Abstract][Full Text] [Related]
3. The overexpression of polycomb group proteins Bmi1 and EZH2 is associated with the progression and aggressive biological behavior of hepatocellular carcinoma.
Sasaki M; Ikeda H; Itatsu K; Yamaguchi J; Sawada S; Minato H; Ohta T; Nakanuma Y
Lab Invest; 2008 Aug; 88(8):873-82. PubMed ID: 18591938
[TBL] [Abstract][Full Text] [Related]
4. Increased polycomb-group oncogene Bmi-1 expression correlates with poor prognosis in hepatocellular carcinoma.
Wang H; Pan K; Zhang HK; Weng DS; Zhou J; Li JJ; Huang W; Song HF; Chen MS; Xia JC
J Cancer Res Clin Oncol; 2008 May; 134(5):535-41. PubMed ID: 17917742
[TBL] [Abstract][Full Text] [Related]
5. Two stem cell markers, ATP-binding cassette, G2 subfamily (ABCG2) and BMI-1, predict the transformation of oral leukoplakia to cancer: a long-term follow-up study.
Liu W; Feng JQ; Shen XM; Wang HY; Liu Y; Zhou ZT
Cancer; 2012 Mar; 118(6):1693-700. PubMed ID: 22009787
[TBL] [Abstract][Full Text] [Related]
6. The polycomb gene product BMI1 contributes to the maintenance of tumor-initiating side population cells in hepatocellular carcinoma.
Chiba T; Miyagi S; Saraya A; Aoki R; Seki A; Morita Y; Yonemitsu Y; Yokosuka O; Taniguchi H; Nakauchi H; Iwama A
Cancer Res; 2008 Oct; 68(19):7742-9. PubMed ID: 18829528
[TBL] [Abstract][Full Text] [Related]
7. The expression of CD90/Thy-1 in hepatocellular carcinoma: an in vivo and in vitro study.
Sukowati CH; Anfuso B; Torre G; Francalanci P; Crocè LS; Tiribelli C
PLoS One; 2013; 8(10):e76830. PubMed ID: 24116172
[TBL] [Abstract][Full Text] [Related]
8. Granulin-epithelin precursor is an oncofetal protein defining hepatic cancer stem cells.
Cheung PF; Cheng CK; Wong NC; Ho JC; Yip CW; Lui VC; Cheung AN; Fan ST; Cheung ST
PLoS One; 2011; 6(12):e28246. PubMed ID: 22194816
[TBL] [Abstract][Full Text] [Related]
9. Canonical Wnt signaling is antagonized by noncanonical Wnt5a in hepatocellular carcinoma cells.
Yuzugullu H; Benhaj K; Ozturk N; Senturk S; Celik E; Toylu A; Tasdemir N; Yilmaz M; Erdal E; Akcali KC; Atabey N; Ozturk M
Mol Cancer; 2009 Oct; 8():90. PubMed ID: 19849855
[TBL] [Abstract][Full Text] [Related]
10. Detection of CD133, Bmi-1, and ABCG2 in ameloblastic tumors.
Kumamoto H; Ohki K
J Oral Pathol Med; 2010 Jan; 39(1):87-93. PubMed ID: 19659474
[TBL] [Abstract][Full Text] [Related]
11. An isocorydine derivative (d-ICD) inhibits drug resistance by downregulating IGF2BP3 expression in hepatocellular carcinoma.
Li M; Zhang L; Ge C; Chen L; Fang T; Li H; Tian H; Liu J; Chen T; Jiang G; Xie H; Cui Y; Yao M; Li J
Oncotarget; 2015 Sep; 6(28):25149-60. PubMed ID: 26327240
[TBL] [Abstract][Full Text] [Related]
12. Bmi1 functions as an oncogene independent of Ink4A/Arf repression in hepatic carcinogenesis.
Xu CR; Lee S; Ho C; Bommi P; Huang SA; Cheung ST; Dimri GP; Chen X
Mol Cancer Res; 2009 Dec; 7(12):1937-45. PubMed ID: 19934271
[TBL] [Abstract][Full Text] [Related]
13. Relevance of two genes in the multidrug resistance of hepatocellular carcinoma: in vivo and clinical studies.
Sun Z; Zhao Z; Li G; Dong S; Huang Z; Ye L; Liang H; Qu J; Ai X; Zhang W; Chen X
Tumori; 2010; 96(1):90-6. PubMed ID: 20437864
[TBL] [Abstract][Full Text] [Related]
14. The polycomb group proteins, BMI-1 and EZH2, are tumour-associated antigens.
Steele JC; Torr EE; Noakes KL; Kalk E; Moss PA; Reynolds GM; Hubscher SG; van Lohuizen M; Adams DH; Young LS
Br J Cancer; 2006 Nov; 95(9):1202-11. PubMed ID: 17024127
[TBL] [Abstract][Full Text] [Related]
15. Differential expression of drug uptake and efflux transporters in Japanese patients with hepatocellular carcinoma.
Namisaki T; Schaeffeler E; Fukui H; Yoshiji H; Nakajima Y; Fritz P; Schwab M; Nies AT
Drug Metab Dispos; 2014 Dec; 42(12):2033-40. PubMed ID: 25231932
[TBL] [Abstract][Full Text] [Related]
16. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical Assessment of the Expression of Biliary Transportation Proteins MRP2 and MRP3 in Hepatocellular Carcinoma and in Cholangiocarcinoma.
Cirqueira CS; Felipe-Silva AS; Wakamatsu A; Marins LV; Rocha EC; de Mello ES; Alves VAF
Pathol Oncol Res; 2019 Oct; 25(4):1363-1371. PubMed ID: 29464551
[TBL] [Abstract][Full Text] [Related]
18. Hepatobiliary transporter expression in human hepatocellular carcinoma.
Zollner G; Wagner M; Fickert P; Silbert D; Fuchsbichler A; Zatloukal K; Denk H; Trauner M
Liver Int; 2005 Apr; 25(2):367-79. PubMed ID: 15780063
[TBL] [Abstract][Full Text] [Related]
19. Gene and functional up-regulation of the BCRP/ABCG2 transporter in hepatocellular carcinoma.
Sukowati CH; Rosso N; Pascut D; Anfuso B; Torre G; Francalanci P; Crocè LS; Tiribelli C
BMC Gastroenterol; 2012 Nov; 12():160. PubMed ID: 23153066
[TBL] [Abstract][Full Text] [Related]
20. SHP2 is induced by the HBx-NF-κB pathway and contributes to fibrosis during human early hepatocellular carcinoma development.
Kang HJ; Chung DH; Sung CO; Yoo SH; Yu E; Kim N; Lee SH; Song JY; Kim CJ; Choi J
Oncotarget; 2017 Apr; 8(16):27263-27276. PubMed ID: 28460481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
